BTIG Maintains Buy on Boston Scientific, Lowers Price Target to $65

Benzinga Newsdesk www.benzinga.com Negative 71.0%

Neg 71% Neu 0% Pos 0%

BTIG analyst Marie Thibault maintains Boston Scientific (NYSE:BSX) with a Buy and lowers the price target from $80 to $65.